Market Overview

Deutsche Bank Optimistic On Fundamentals In Life Science Tools/Diagnostics Sector

Share:
Deutsche Bank Optimistic On Fundamentals In Life Science Tools/Diagnostics Sector
Related A
Unisys ClearPath Software Selected by Malaysia's ANGKASA
Why Agilent Technologies (A) Stock Might be a Great Pick
Related BIO
With 'Tunnel's End' In Sight, Deutsche Upgrades Bio-Rad Labs
Benzinga's Top Upgrades, Downgrades For June 28, 2017

Deutsche Bank initiated coverage of 16 companies in the Life Science Tools & Diagnostics sector, with a generally positive view on sector fundamentals, and the bank considers the end market environment more stable than stock volatility suggests.

Life Sciences Tools & Diagnostics Sector

Despite upcoming challenges in capital deployment, secular product cycles and long-term margin expansion, the brokerage is optimistic on the sector citing secular growth drivers, intellectual property, barriers to entry, high margins and recurring revenue.

Deutsche Bank noted that secular trends benefiting the sector include precision medicine, emerging market growth and enhanced regulatory scrutiny.

“The clinical diagnostics sector is a channel for many innovations borne of the research tools sector, such as testing which can improve the specificity of cancer prognosis and identify abnormalities in unborn babies,” analyst Dan Leonard wrote in a note.

Further, Leonard is optimistic on the tools sector fundamentals for the next couple of years, driven by growth in biopharma, China spending on scientific research, food and environmental testing, volume growth in diagnostics and continued consolidation opportunity.

On the lab industry front, the analyst believes short-term pricing pain could actually hasten a long-term volume gain opportunity for larger labs. The analyst also pointed out potential benefits from improvement in reimbursement coverage and potential rationalized pricing in areas of esoteric diagnostics.

Buy-Rated Stocks

Following are Leonard’s Buy-rated stocks with price targets:

  • Agilent Technologies Inc (NYSE: A): $54.
  • Quest Diagnostics Inc (NYSE: DGX): $108.
  • Danaher Corporation (NYSE: DHR): $88.
  • Hologic, Inc. (NASDAQ: HOLX): $48.
  • Laboratory Corp. of America Holdings (NYSE: LH): $170.
  • BIO-TECHNE Corp (NASDAQ: TECH): $115.
  • Thermo Fisher Scientific Inc. (NYSE: TMO): $163.
  • Waters Corporation (NYSE: WAT): $160.

Hold-Rated Stocks

Following is the list of Deutsche Bank’s Hold-rated stocks in the

  • Bio-Rad Laboratories, Inc. (NYSE: BIO): $195.
  • Bruker Corporation (NASDAQ: BRKR): $24.
  • Genomic Health, Inc. (NASDAQ: GHDX): $31.
  • Illumina, Inc. (NASDAQ: ILMN): $160.
  • Mettler-Toledo International Inc. (NYSE: MTD): $420.
  • PerkinElmer, Inc. (NYSE: PKI): $55.
  • VWR Corp (NASDAQ: VWR): $26.

And 2 Sell-Rated Stocks

Meanwhile, Leonard is Sell-rated on Luminex Corporation (NASDAQ: LMNX) and Myriad Genetics, Inc. (NASDAQ: MYGN), with price targets of $18 and $15, respectively.

Latest Ratings for A

DateFirmActionFromTo
Jul 2017Wells FargoUpgradesMarket PerformOutperform
Jul 2017Morgan StanleyMaintainsOverweight
Mar 2017Morgan StanleyUpgradesEqual-WeightOverweight

View More Analyst Ratings for A
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Short Ideas Health Care Price Target Initiation Top Stories Best of Benzinga

 

Related Articles (A + BIO)

View Comments and Join the Discussion!